Predicting Immunotherapy Response in Bladder Cancer

ROBERT DREICER, MD

Thursday, March 21, 2019

When it comes to predicting response to checkpoint inhibitors for patients with urothelial carcinoma, PD-L1 status may not be the most accurate factor, explained Robert Dreicer, MD, deputy director of UVA Cancer Center, director of solid tumor oncology within the division of hematology/oncology and is a professor of medicine and urology at the University of Virginia.

PD-L1 is not the most reliable predictor because there are many patients whose tumors are not PD-L1 positive who still respond to immunotherapy. More research in this field is still warranted.

Discussions >>

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.

Related Videos

It Takes a Team: Treating Adverse Events

By: Matthew A. Gubens, MD

Risks Versus Benefits in Combining Immunotherapies

By: Ryan J. Sullivan, MD

By: Jarushka Naidoo, MBBCh